What is Chimera Bioengineering?
Based in South San Francisco, Chimera Bioengineering is a pioneering biotechnology firm dedicated to the advancement of CAR-T cell therapy. The company utilizes sophisticated genetic engineering technology to enhance the efficacy and safety profiles of cell-based cancer treatments. By focusing on the development of engineered T-cells that specifically target tumor antigens, Chimera addresses the historical limitations of immunotherapy in solid tumor environments. Their mission is to fundamentally transform the oncology treatment paradigm, providing innovative, immune-mediated therapies that prioritize patient outcomes and therapeutic precision. The company's operational focus remains on scaling its manufacturing capabilities and advancing its clinical trials to meet the urgent demand for more effective cancer interventions.
How much funding has Chimera Bioengineering raised?
Chimera Bioengineering has raised a total of $385K across 2 funding rounds:
Debt
$150K
Debt
$235K
Debt (2020): $150K with participation from PPP
Debt (2021): $235K led by PPP
Key Investors in Chimera Bioengineering
PPP
Public-Private Partnership
What's next for Chimera Bioengineering?
With the recent influx of capital, Chimera Bioengineering is well-positioned to advance its lead candidates through critical clinical milestones. The company's strategic roadmap involves expanding its research and development infrastructure to address the technical hurdles of solid tumor infiltration. Investors are closely monitoring the firm's ability to translate its genetic engineering breakthroughs into scalable, commercial-ready therapies. As the company moves into this next phase of growth, the focus will likely shift toward regulatory engagement and potential strategic partnerships that could further validate its platform. The sustained financial support provides the necessary runway to navigate the high-stakes environment of late-stage clinical trials, ultimately aiming to redefine the standard of care for patients battling aggressive malignancies.
See full Chimera Bioengineering company page
